Abstract
This article is directed primarily at how clinical trials can be ethically conducted in the midst of the current global COVID-19 pandemic. We explain why ethical issues are more complicated than they once were. Furthermore, we discuss the relevant parties` roles in protecting participants` rights and in keeping basic research ethics of justice, respect, equity, and beneficence strongly implemented on the ground.
 
 References
 
 Moorthy V, Restrepo H, Preziosi MP, Swaminathan S. Data sharing for novel coronavirus (COVID-19). Bull World Health Organ. 2020; 98: 150. http://dx.doi.org/10.2471/BLT.20.251561
 Angus DC. Optimizing the trade-off between learning and doing in a pandemic. Epub ahead of print, 2020. https://doi.org/10.1001/jama.2020.4984)JAMA
 Park YR, Koo H, Yoon YK, Park S, Lim Y-S, Baek S, et al. Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study. JMIR Med Inform. 2020;8(2): e14379. https://doi.org/2196/14379.
 Bae J, Lee J, Jang Y, Lee Y. Development of simulation education debriefing protocol with faculty guide for enhancement clinical reasoning. BMC Med Educ. 2019;19(1):197. https://doi.org/10.1186/s12909-019-1633-8.
 Cox EM, Edmund AV, Kratz E, Lockwood SH, Shankar A. Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways. Clin Transl Sci. 2020;13(3):451‐ https://doi.org/10.1111/cts.12745. Epub 2020 Feb 6.
 Rivenbark JG, Ichou M. Discrimination in healthcare as a barrier to care: experiences of socially disadvantaged populations in France from a nationally representative survey. BMC Public Health. 2020;20(1):31. https://doi.org/1186/s12889-019-8124-z
 Arsenijevic J, Tummers L, Bosma N. Adherence to Electronic Health Tools Among Vulnerable Groups: Systematic Literature Review and Meta-Analysis. J Med Internet Res. 2020;22(2): e11613. https://doi.org/2196/11613
 Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing: An overview. Vaccine. 2017;35(33):4064–71. https://doi.org/1016/j.vaccine.2017.06.003.
 Deming D. Do extraordinary claims require extraordinary evidence? Philosophia (Ramat Gan). 2016;44(4):1319‐ https://doi.org/10.3389/fpsyg.2011.00117
Highlights
In the time of COVID-19, where coronavirus disease has spread across the globe infecting the four corners of the Earth, research centers and major laboratories are frantically racing to come forward with a medicinal formula that kills the virus and ends the hardship
Amid the unprecedented international storm, research bioethics loom large among the many things that will never be taken for granted again as COVID-19 crises continue
Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated
Summary
In the time of COVID-19, where coronavirus disease has spread across the globe infecting the four corners of the Earth, research centers and major laboratories are frantically racing to come forward with a medicinal formula that kills the virus and ends the hardship. Working in a collaborative team Today, people worldwide are in one trench facing a common threat, and monitoring the pandemic spread in grave concern They look highly on scientists and researchers to guide the ship to a safe harbor. Debriefing at research centers Debriefing is an informal experience exchange session designed to improve team performance and effectiveness from lessons learned and reinforce positive behaviors It is a high qualitystandard implemented in different industries, where the health industry is no exception [4]. The study results would carry many specifications to the minority worked upon, and, it will not be reliably generalizable – ruining the external validity of the research Participants, whatever minority they belong to, should not be denied health services related to COVID-19 as public health is the major concern at this point. In an attempt to minimize the potential biohazard on participants, health workers, and research sites, The NIH group suggests developing a special “challenge strain” with reduced virulence to administer in challenge trials
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
